OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 19, 2016 -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced participation in two upcoming scientific conferences.
- World Orphan Drug Congress – Washington, D.C. (April 20-22)
Eric Olson, Senior Director, Corporate Development will give a presentation entitled “A novel AAV-based gene therapy platform for the treatment of rare diseases” at 4:00pm EDT on Thursday, April 21 during which he will discuss AGTC’s proprietary gene therapy platform.
- Retinal Cell and Gene Therapy Innovation Summit – Seattle, Wash. (April 28-29)
Jeff Chulay, M.D., DTM&H, Vice President and Chief Medical Officer, will lead a session about AGTC’s clinical development programs on Thursday, April 28 entitled “Development of AAV Gene Therapy Vectors for Achromatopsia and X-Linked Retinitis Pigmentosa.”
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function, and which currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis, X-linked retinitis pigmentosa, achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and early research studies in additional indications. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
IR/PR CONTACTS: David Carey (IR) or Danielle Lewis (PR) Lazar Partners Ltd. T: (212) 867-1768 or (212) 843-0211 [email protected] or [email protected] CORPORATE CONTACTS: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204 [email protected] Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected]
